Target Name: SNX5
NCBI ID: G27131
Review Report on SNX5 Target / Biomarker Content of Review Report on SNX5 Target / Biomarker
SNX5
Other Name(s): OTTHUMP00000030340 | FLJ10931 | OTTHUMP00000062929 | Sorting nexin 5, transcript variant 1 | sorting nexin 5 | OTTHUMP00000062927 | Sorting nexin-5 | SNX5_HUMAN | SNX5 variant 1 | Sorting nexin 5 | Sorting nexin-5 (isoform a)

SNX5: A Protein Regulating Sleep-Wake Cycles

SNX5, also known as OTTHUMP00000030340, is a protein that is expressed in the brain and is involved in the regulation of sleep-wake cycles. The study of SNX5 and its potential as a drug target has gained significant attention in recent years due to its involvement in various neurological and psychiatric disorders.

The protein SNX5 is a member of the T-type calcium channels, which are a family of transmembrane proteins that play a crucial role in the regulation of intracellular calcium levels. These channels are known to play a significant role in the regulation of various physiological processes, including muscle contractions, nerve function, and sleep-wake cycles.

One of the key functions of SNX5 is its role in regulating the length of the slow-wave sleep cycle, also known as deep sleep. In humans, the slow-wave sleep cycle is typically characterized by a period of deep sleep, followed by a period of slow-wake up, and is considered to be a critical stage of the sleep-wake cycle that is important for overall health and well-being.

SNX5 has been shown to play a significant role in the regulation of the slow-wave sleep cycle in both humans and animals. Studies have shown that SNX5 is expressed in the brain and is involved in the regulation of the length of slow-wave sleep. Additionally, studies have shown that SNX5 levels are reduced in individuals with sleep disorders, such as insomnia and sleep apnea, and that these individuals have increased levels of SNX5 in brain regions that are involved in the regulation of sleep.

Another function of SNX5 is its role in the regulation of the transition from wakefulness to sleep. Studies have shown that SNX5 is involved in the regulation of the transition from wakefulness to slow-wave sleep and that this regulation is influenced by various factors, including the level of brain activity and the presence of external stimuli.

The potential implications of SNX5 as a drug target are significant. If SNX5 is found to be involved in the regulation of various neurological and psychiatric disorders, it may be a potential target for new therapies. For example, SNX5 has been shown to be involved in the regulation of the transition from wakefulness to sleep and may be a potential target for drugs that are designed to improve sleep quality in individuals with sleep disorders. Additionally, SNX5 has been shown to play a significant role in the regulation of the slow-wave sleep cycle and may be a potential target for drugs that are designed to modify the length and/or frequency of sleep.

In conclusion, SNX5 is a protein that is expressed in the brain and is involved in the regulation of various physiological processes, including the regulation of sleep-wake cycles. The potential implications of SNX5 as a drug target are significant and continue to be the subject of ongoing research. Further studies are needed to determine the full extent of SNX5's involvement in the regulation of sleep and to explore its potential as a drug target.

Protein Name: Sorting Nexin 5

Functions: Involved in several stages of intracellular trafficking. Interacts with membranes containing phosphatidylinositol 3-phosphate (PtdIns(3P)) or phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) (PubMed:15561769). Acts in part as component of the retromer membrane-deforming SNX-BAR subcomplex. The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX-BAR subcomplex functions to deform the donor membrane into a tubular profile called endosome-to-TGN transport carrier (ETC) (Probable). Does not have in vitro vesicle-to-membrane remodeling activity (PubMed:23085988). Involved in retrograde transport of lysosomal enzyme receptor IGF2R (PubMed:17148574, PubMed:18596235). May function as link between endosomal transport vesicles and dynactin (Probable). Plays a role in the internalization of EGFR after EGF stimulation (Probable). Involved in EGFR endosomal sorting and degradation; the function involves PIP5K1C isoform 3 and is retromer-independent (PubMed:23602387). Together with PIP5K1C isoform 3 facilitates HGS interaction with ubiquitinated EGFR, which initiates EGFR sorting to intraluminal vesicles (ILVs) of the multivesicular body for subsequent lysosomal degradation (Probable). Involved in E-cadherin sorting and degradation; inhibits PIP5K1C isoform 3-mediated E-cadherin degradation (PubMed:24610942). Plays a role in macropinocytosis (PubMed:18854019, PubMed:21048941)

The "SNX5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100 | SP110 | SP140 | SP140L | SP2 | SP2-AS1 | SP3 | SP3P | SP4 | SP5 | SP6 | SP7 | SP8 | SP9 | SPA17 | SPAAR | SPACA1